Lineage Cell Therapeutics, Inc. Business Acquisition, Pro Forma Revenue
Lineage Cell Therapeutics, Inc. (LCTX) reported Business Acquisition, Pro Forma Revenue of $2.75 million for the 9-month period ending 2014-09-30, per its 10-Q filed 2014-11-07.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2014-11-07
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2014-09-30 was $961.31K, a 39.24% decline year-over-year.
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2014-06-30 was $855.36K.
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2014-03-31 was $934.72K, a 89.33% increase year-over-year.
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2013-12-31 was $2.38M, a 94.60% increase year-over-year.
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma revenue for fiscal 2013 was $4.43M, a 5.40% increase from fiscal 2012.
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma revenue for fiscal 2012 was $4.21M, a 17.70% decline from fiscal 2011.
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma revenue for fiscal 2011 was $5.11M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 3 month as first filed | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 6 month as first filed | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 9 month as first filed | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|---|---|---|
| 2014-09-30 | $961.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $1.82M derived: sum of 2 quarters · filed 2014-11-07 | $2.75M 10-Q · filed 2014-11-07 | $5.13M derived: sum of 4 quarters · filed 2014-11-07 | |||
| 2014-06-30 | $855.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $1.79M 10-Q · filed 2014-08-11 | $4.17M derived: sum of 3 quarters · filed 2014-08-11 | $5.75M derived: sum of 4 quarters · filed 2014-11-07 | |||
| 2014-03-31 | $934.72K 10-Q · filed 2014-05-12 | $3.31M derived: sum of 2 quarters · filed 2014-05-12 | $4.90M derived: sum of 3 quarters · filed 2014-11-07 | $4.88M derived: sum of 4 quarters · filed 2014-11-07 | |||
| 2013-12-31 | $2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $3.96M derived: sum of 2 quarters · filed 2014-11-07 | $3.94M derived: sum of 3 quarters · filed 2014-11-07 | $4.43M 10-K · filed 2014-03-17 | |||
| 2013-09-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $1.56M derived: sum of 2 quarters · filed 2014-11-07 | $2.06M 10-Q · filed 2014-11-07 | $2.54M 10-Q · filed 2013-11-12 | $3.28M derived: sum of 4 quarters · filed 2014-11-07 | ||
| 2013-06-30 | -$20.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $473.07K 10-Q · filed 2014-08-11 | $1.82M 10-Q · filed 2013-08-09 | $1.70M derived: sum of 3 quarters · filed 2014-08-11 | $2.81M derived: sum of 4 quarters · filed 2014-08-11 | ||
| 2013-03-31 | $493.70K 10-Q · filed 2014-05-12 | $614.47K 10-Q · filed 2013-05-10 | $1.72M derived: sum of 2 quarters · filed 2014-05-12 | $2.83M derived: sum of 3 quarters · filed 2014-05-12 | $3.89M derived: sum of 4 quarters · filed 2014-05-12 | ||
| 2012-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $2.33M derived: sum of 2 quarters · filed 2014-03-17 | $3.40M derived: sum of 3 quarters · filed 2014-03-17 | $4.21M 10-K · filed 2014-03-17 | |||
| 2012-09-30 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $2.18M derived: sum of 2 quarters · filed 2013-11-12 | $2.98M 10-Q · filed 2013-11-12 | $4.81M derived: sum of 4 quarters · filed 2013-11-12 | |||
| 2012-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $1.87M 10-Q · filed 2013-08-09 | $3.70M derived: sum of 3 quarters · filed 2013-08-09 | $5.04M derived: sum of 4 quarters · filed 2013-08-09 | |||
| 2012-03-31 | $808.79K 10-Q · filed 2013-05-10 | $2.64M derived: sum of 2 quarters · filed 2013-05-10 | $3.98M derived: sum of 3 quarters · filed 2013-05-10 | ||||
| 2011-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $3.17M derived: sum of 2 quarters · filed 2013-03-18 | $5.11M 10-K · filed 2013-03-18 | ||||
| 2011-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $3.29M 10-Q · filed 2012-11-09 | |||||
| 2011-06-30 | $1.94M 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |